Moberg Pharma AB Year-end report 2017
STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDAPERIOD (FULL YEAR 2017)* · Net revenue SEK 439.0 million (334.3) · EBITDA SEK 89.4 million (77.9) · EBITDA margin 20% (23) · EBITDA for current product portfolio SEK 106.0 million (93.5) · Operating profit (EBIT) SEK 51.1 million (62.2) · Net profit after tax SEK 11.1 million (32.7) · Diluted earnings per share SEK 0.64 (2.25) · Operating cash flow per share SEK 3.07 (-1.24) · The Board of Directors proposes that no dividend be paid for the 2017 financial year FOURTH QUARTER (OCT-DEC 2017) · Net revenue SEK